Specify a stock or a cryptocurrency in the search bar to get a summary
Agios Pharm
AGIOAgios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. Address: 88 Sidney Street, Cambridge, MA, United States, 02139
Analytics
WallStreet Target Price
56.2 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures AGIO
Dividend Analytics AGIO
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History AGIO
Stock Valuation AGIO
Financials AGIO
Results | 2019 | Dynamics |